Case (ref) | Age (years) | Testis | Tumour size | Stage | Histo | Grade | Treat | Outcome | Bcl-2 | CD10 | Bcl-6 | p53 | IgH/R | IgH/M | BCL-2/R | BCL-6/R | BCL-6/M | DAP |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bcl-2, Bcl-2 protein immunostaining; Bcl-6, Bcl–6 protein immunostaining; BCL-2/R, BCL-2 gene rearrangement; BCL-6/R, BCL-6 gene rearrangement; BCL-6/M, BCL-6 gene somatic mutations; CD10, CD10 immunostaining; CX, chemotherapy; DAP, DAP kinase gene hypermethylation; E, extranodal; F, follicular; F&D, follicular and diffuse; Histo, histology; IgH/M, IgVH gene somatic mutations; IgH/R, IgVH gene clonal rearrangement; NA, not available; NED, no evidence of disease; OR, orchiectomy; p53, p53 product immunostaining; Treat, treatment; –, negative result; +, positive result. | ||||||||||||||||||
*Follow up updated in Finn et al.14 | ||||||||||||||||||
1 (13) | 8 | Left | 2.0 cm | IE | F | 3 | OR | NED/44 mo* | – | NA | NA | NA | Clonal | NA | – | NA | NA | NA |
2 (14) | 3 | Left | 2.8 cm | IE | F&D | 3 | OR+CX | NED/18 mo | – | – | + | – | – | NA | – | NA | NA | NA |
3 (14) | 3 | Right | 2.3 cm | IE | F | 3 | OR+CX | NED/18 mo | – | – | + | – | Clonal | NA | – | + | NA | NA |
4 (14) | 10 | Left | 4.0 cm | IE | F | 3 | OR+CX | NED/19 mo | – | NA | + | – | Clonal | NA | – | NA | NA | NA |
5 (14) | 5 | Right | 4.0 cm | IE | F | 3 | OR+CX | NED/24 mo | – | NA | NA | – | NA | NA | NA | NA | NA | NA |
6 (15) | 6 | Right | 3.0 cm | IE | F&D | 3 | OR+CX | NED/7 mo | – | + | + | – | NA | NA | – | NA | NA | NA |
7 (present case) | 4 | Left | 2.0 cm | IE | F&D | 3 | OR+CX | NED/26 mo | – | + | + | – | Clonal | + | – | NA | + | – |